Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Thursday, April 3rd, IPO Scoop reports. The company will be issuing 2,700,000 shares at $7.50-$8.50 per share. The ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Wednesday, April 2nd, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.50-$8.50 per share. The ...